In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2011

Executive Summary

Of the $6.3 billion total raised, 32% was from China distributor Shanghai Pharmaceuticals' $1.99 billion IPO - not only Q2's biggest financing, but also the second-largest pharma IPO of all time. Six of the 26 completed mergers were done to gain access to emerging markets, most notably, Takeda's $13.7 billion buy of Nycomed, almost half of the total $27.9 billion spent on pharma acquisitions this quarter. Q2's largest alliance was Vertex's in-licensing of Alios BioPharma's preclinical HCV nucleotide analogues, a deal that could be worth up to $775 million in up fronts and development milestones.
Advertisement

Related Content

Pfizer: Established Products And Consumer Health In; Animal Health And Nutrition Out
Pfizer: Established Products And Consumer Health In; Animal Health And Nutrition Out
After A Record Year, China Healthcare IPOs Have Endured A Tough 2011
Valeant Expands Dermatology In Staged Deal With Meda
Abbott Refreshes Rheumatoid Arthritis Strategy By Licensing Biotest's Phase II Candidate
Abbott Refreshes Rheumatoid Arthritis Strategy By Licensing Biotest's Phase II Candidate
Vertex Prepares For HCV Combo Research By Licensing Two Compounds From Alios
Vertex Prepares For HCV Combo Research By Licensing Two Compounds From Alios
North American Buyers Turn to European Branded Generics For Growth
North American Buyers Turn to European Branded Generics For Growth

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003692

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel